Invesco Biotechnology & Genome ETF
Filed by Invesco Exchange-Traded Fund Trust. What this fund reported holding in its latest quarterly NPORT-P. Positions are ordered by share of the fund rather than by size, because that is what separates a conviction from a rounding error.
What it holds
Largest share of the fund first.
| Company | % of fund | Value |
|---|---|---|
| REGNRegeneron Pharmaceuticals Inc | 5.47% | $15.4M |
| AMGNAmgen Inc | 5.22% | $14.7M |
| CDNACareDx Inc | 5.04% | $14.2M |
| VRTXVertex Pharmaceuticals Inc | 4.99% | $14.1M |
| BIIBBiogen Inc | 4.79% | $13.5M |
| GILDGilead Sciences, Inc | 4.43% | $12.5M |
| UTHRUnited Therapeutics Corp | 4.08% | $11.5M |
| TECHBio-Techne Corp | 3.73% | $10.5M |
| ILMNIllumina Inc | 3.51% | $9.9M |
| ALNYAlnylam Pharmaceuticals Inc | 3.17% | $8.9M |
| INCYIncyte Corp | 3.06% | $8.6M |
| RGENRepligen Corp | 3.04% | $8.6M |
| ACADACADIA Pharmaceuticals Inc | 3.02% | $8.5M |
| HALOHalozyme Therapeutics Inc | 2.98% | $8.4M |
| BMRNBioMarin Pharmaceutical Inc | 2.82% | $8M |
| NBIXNeurocrine Biosciences Inc | 2.66% | $7.5M |
| EXELExelixis Inc | 2.64% | $7.4M |
| BCRXBioCryst Pharmaceuticals Inc | 2.63% | $7.4M |
| VCYTVeracyte Inc | 2.60% | $7.3M |
| SRPTSarepta Therapeutics Inc | 2.21% | $6.2M |
Source: NPORT-P filings, via EDGAR. Positions arrive by CUSIP, and only a CUSIP verified against a ticker is kept — so this is what we could match, not everything the fund holds, and the matched value is therefore below the fund's own size. A balance is shares where the filing says `NS` and a principal amount where it says `PA`, which is why it is not labelled shares in both cases.
Follow Invesco Biotechnology & Genome ETF by email
Invesco Biotechnology & Genome ETF's new holdings reports, with the rest of the week's filings. One email a week, free.
Unsubscribe with one click from any email.